search
Back to results

The Effects of Stromal Vascular Fraction and Mesenchymal Stem Cells as Intra-articular Injection in Knee Joint Osteoarthritis

Primary Purpose

Osteoarthritis

Status
Withdrawn
Phase
Phase 2
Locations
Iran, Islamic Republic of
Study Type
Interventional
Intervention
Mesenchymal stem cell
Placebo
Sponsored by
SCARM Institute, Tabriz, Iran
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Osteoarthritis focused on measuring Joint Diseases, Musculoskeletal Diseases, Arthritis

Eligibility Criteria

25 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Osteoarthritis diagnosed by MRI

Exclusion Criteria:

  • Pregnancy or lactating
  • Positive tests for HIV, Hepatitis C virus (HCV), Hepatitis C virus (HBV)
  • Active neurologic disorder
  • End organ damage
  • Uncontrolled endocrine disorder

Sites / Locations

  • SCARM Institute

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

mesenchymal stem cell

placebo

Arm Description

Patients with knee joint osteoarthritis who underwent intra articular mesenchymal stem cell injection

The patients who are in control group and underwent placebo injection

Outcomes

Primary Outcome Measures

physical function improvement
Evaluation the physical function improvement Measured by WOMAC osteoarthritis index after cell injection
Change in pain density
Evaluation the changing of pain density measured by Visual Analogue Scale after cell injection

Secondary Outcome Measures

Joint swelling
Evaluation the joint swelling by physical examination after intra articular cell injection
Joint erythema
Evaluation the joint erythema by physical examination after cell injection
Deterioration of joint function
Evaluation the deterioration of joint function by physical examination after intra articular cell injection
Allergic reactions
Evaluation the allergic reactions like skin rash,skin erythema, dyspnea by physical examination after cell injection

Full Information

First Posted
May 21, 2017
Last Updated
March 16, 2020
Sponsor
SCARM Institute, Tabriz, Iran
search

1. Study Identification

Unique Protocol Identification Number
NCT03164083
Brief Title
The Effects of Stromal Vascular Fraction and Mesenchymal Stem Cells as Intra-articular Injection in Knee Joint Osteoarthritis
Official Title
Evaluation the Effects of Intra-articular Injection of Mesenchymal Stem Cells and Stromal Vascular Fraction Patients With Knee Joint Osteoarthritis, Triple Blind Randomized Clinical Trial
Study Type
Interventional

2. Study Status

Record Verification Date
January 2019
Overall Recruitment Status
Withdrawn
Why Stopped
not approved by sponsor
Study Start Date
November 10, 2019 (Anticipated)
Primary Completion Date
August 21, 2020 (Anticipated)
Study Completion Date
December 5, 2020 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
SCARM Institute, Tabriz, Iran

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Osteoarthritis of the knee is one of the most common causes of disability among elderly. As the disease progresses the cartilage become frustrated, surrounding bone react to become thicker and inflammation occurs in subchondral bone seen in T2-weighted MRI as increase in signal density. Patients are treated initially by pain management. In patients who don't response to first line treatment invasive treatment like total knee replacement is done. The investigators designed this clinical study with the aim of evaluating therapeutic effects of intra-articular injection of bone marrow Mesenchymal Stem Cells (MSC) and stromal Vascular Fraction (SVF) in patients with severe knee osteoarthritis
Detailed Description
This is single center, randomized, triple blind phase II clinical study. Patients will be divided into two groups of case and control. All subjects will undergo bone marrow aspiration. Mesenchymal Stem Cells will be isolated from bone marrow and stromal Vascular Fraction fram lipoaspirate, cultured and transplanted back to the knee joint. Patients of case group will receive cell injection 1 and 4 months after bone marrow aspiration. Placebo will be administered in this group 6 months after the first injection. Patients of control group will receive placebo 1 and 4 months after bone marrow aspiration. They all receive cell injection 6 months after first placebo injection. Follow up visit will occur at 2 and 6 weeks, and 3 and 6 months after the first injection. Radiological exams will be performed before and 6 months after the first injection by MRI. Clinical quantitative assessment will measure joint function by the WOMAC index and pain by the visual analogue scale

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteoarthritis
Keywords
Joint Diseases, Musculoskeletal Diseases, Arthritis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Arm Title
mesenchymal stem cell
Arm Type
Experimental
Arm Description
Patients with knee joint osteoarthritis who underwent intra articular mesenchymal stem cell injection
Arm Title
placebo
Arm Type
Experimental
Arm Description
The patients who are in control group and underwent placebo injection
Intervention Type
Biological
Intervention Name(s)
Mesenchymal stem cell
Intervention Description
intra articular injection of mesenchymal stem cell Other Name: stem cell transplantation
Intervention Type
Biological
Intervention Name(s)
Placebo
Intervention Description
Patients with knee joint osteoarthritis who underwent intra articular placebo injection
Primary Outcome Measure Information:
Title
physical function improvement
Description
Evaluation the physical function improvement Measured by WOMAC osteoarthritis index after cell injection
Time Frame
2 weeks
Title
Change in pain density
Description
Evaluation the changing of pain density measured by Visual Analogue Scale after cell injection
Time Frame
2 weeks
Secondary Outcome Measure Information:
Title
Joint swelling
Description
Evaluation the joint swelling by physical examination after intra articular cell injection
Time Frame
3 months
Title
Joint erythema
Description
Evaluation the joint erythema by physical examination after cell injection
Time Frame
3 months
Title
Deterioration of joint function
Description
Evaluation the deterioration of joint function by physical examination after intra articular cell injection
Time Frame
3 months
Title
Allergic reactions
Description
Evaluation the allergic reactions like skin rash,skin erythema, dyspnea by physical examination after cell injection
Time Frame
3 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
25 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Osteoarthritis diagnosed by MRI Exclusion Criteria: Pregnancy or lactating Positive tests for HIV, Hepatitis C virus (HCV), Hepatitis C virus (HBV) Active neurologic disorder End organ damage Uncontrolled endocrine disorder
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mohammad Nouri, Ph.D
Organizational Affiliation
Head of SCARM Institute
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Peyman Keyhanvar, MD, Ph.D
Organizational Affiliation
Deputy for translational medicine of SCARM institute
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Seyed Kazem Shakouri, Physiatrist
Organizational Affiliation
Tabriz University of Medical Sciences
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Neda keyhanvar, Ph.D
Organizational Affiliation
SCARM institute
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Sepideh Bastani, MSc
Organizational Affiliation
SCARM institute
Official's Role
Principal Investigator
Facility Information:
Facility Name
SCARM Institute
City
Tabriz
Country
Iran, Islamic Republic of

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
28143470
Citation
Pak J, Lee JH, Park KS, Park M, Kang LW, Lee SH. Current use of autologous adipose tissue-derived stromal vascular fraction cells for orthopedic applications. J Biomed Sci. 2017 Jan 31;24(1):9. doi: 10.1186/s12929-017-0318-z.
Results Reference
result
PubMed Identifier
26881220
Citation
Pak J, Lee JH, Kartolo WA, Lee SH. Cartilage Regeneration in Human with Adipose Tissue-Derived Stem Cells: Current Status in Clinical Implications. Biomed Res Int. 2016;2016:4702674. doi: 10.1155/2016/4702674. Epub 2016 Jan 6.
Results Reference
result
PubMed Identifier
24326779
Citation
Koh YG, Choi YJ, Kwon SK, Kim YS, Yeo JE. Clinical results and second-look arthroscopic findings after treatment with adipose-derived stem cells for knee osteoarthritis. Knee Surg Sports Traumatol Arthrosc. 2015 May;23(5):1308-16. doi: 10.1007/s00167-013-2807-2. Epub 2013 Dec 11.
Results Reference
result
PubMed Identifier
22807102
Citation
Pires de Carvalho P, Hamel KM, Duarte R, King AG, Haque M, Dietrich MA, Wu X, Shah F, Burk D, Reis RL, Rood J, Zhang P, Lopez M, Gimble JM, Dasa V. Comparison of infrapatellar and subcutaneous adipose tissue stromal vascular fraction and stromal/stem cells in osteoarthritic subjects. J Tissue Eng Regen Med. 2014 Oct;8(10):757-62. doi: 10.1002/term.1565. Epub 2012 Jul 16.
Results Reference
result

Learn more about this trial

The Effects of Stromal Vascular Fraction and Mesenchymal Stem Cells as Intra-articular Injection in Knee Joint Osteoarthritis

We'll reach out to this number within 24 hrs